glucose, (beta-d)-isomer has been researched along with Chronic Kidney Diseases in 126 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 45 (35.71) | 24.3611 |
| 2020's | 81 (64.29) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, Z; Guo, J; Jiang, HX; Liu, BL; Liu, WJ; Liu, YN; Wang, Y; Xia, CH; Zhang, W; Zhu, ZB | 1 |
| Cherney, D; Chertow, GM; Correa-Rotter, R; Dwyer, JP; Greene, T; Heerspink, HJL; Kosiborod, M; Langkilde, AM; McMurray, JJV; Postmus, D; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Lo, KB; Mathew, RO; Rangaswami, J; Vaduganathan, M | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Nowicki, M; Rossing, P; Sjöström, CD; Stefansson, BV; Toto, RD; Wheeler, DC; Wittmann, I | 1 |
| Deerochanawong, C; Permsuwan, U; Pojchaijongdee, N; Thongsuk, D; Vareesangthip, K | 1 |
| Jardine, MJ; O'Hara, DV | 1 |
| Aluri, KZ; Chertow, GM; Cusick, MM; Goldhaber-Fiebert, JD; Handley, TJ; Joyner, AKC; Owens, DK; Salomon, JA; Tisdale, RL | 1 |
| Aijaz, SS; Iqbal, Y; Zafar, Y | 1 |
| Chan, ATP; Tang, SCW | 1 |
| Cherney, DZI; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Jongs, N; Langkilde, AM; Mann, JFE; McMurray, JJV; Mosenzon, O; Rossing, P; Stefansson, BV; Toto, RD; Vart, P; Waijer, SW; Wheeler, DC | 1 |
| Agarwal, R; Elsäßer, A; Hauske, SJ; Kadowaki, T; Levin, A; Nangaku, M; Ritter, I; Steubl, D; Tuttle, KR; Wanner, C; Wheeler, DC | 1 |
| Miyagi, K; Miyazaki, R | 1 |
| Kurata, Y; Nangaku, M | 1 |
| Matsumoto, K; Tsuboi, N; Ueda, H; Yokoo, T | 1 |
| Grätzel von Grätz, P | 1 |
| Ando, J; Kodera, S; Komuro, I; Morita, H; Nishi, H; Takeda, N | 1 |
| Aleksandric, M; Fülöp, T; Gumprecht, J; Kamenov, Z; Medvedchikov, A; Prázný, M; Rosenzweig, D; Suplotova, L | 1 |
| Cho, GY; Choi, HM; Hwang, IC; Lim, J; Yoon, YE | 1 |
| Bergenheim, K; Briggs, A; Darlington, O; Garcia Sanchez, JJ; Heerspink, HJL; McEwan, P; McMurray, JJV; Miller, R; Wheeler, DC | 1 |
| Bartholdy, KV; Biering-Sørensen, T; Bressendorff, I; Christensen, J; Feldt-Rasmussen, B; Hansen, D; Haynes, R; Jensen, J; Johansen, ND; Køber, L; Landler, N; Persson, F; Rossing, P; Schou, M; Skaarup, KG; Solomon, S; Vaduganathan, M; Zannad, F | 1 |
| Beernink, JM; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Jongs, N; Langkilde, AM; Laverman, GD; McMurray, JJV; Persson, F; Rossing, P; Sjöström, CD; Toto, RD; Wheeler, DC | 1 |
| Iwata, Y; Kawamura, Y; Mitani, W; Morimoto, M; Notsu, S; Tamai, S; Yamato, M | 1 |
| Cauchon, M; Lanthier, L; Plourde, ME; Viau-Trudel, A | 1 |
| Bongard, A | 1 |
| Chertow, GM; Heerspink, HJL; Jongs, N; Langkilde, AM; Vart, P; Wheeler, DC | 1 |
| Higashi, Y; Hirai, H; Hisauchi, I; Inagaki, S; Kamei, N; Kono, T; Kurozumi, A; Maruhashi, T; Node, K; Okada, Y; Oshita, C; Shimabukuro, M; Sonoda, S; Sugimoto, K; Taguchi, I; Takahashi, K; Tanaka, A; Teragawa, H; Torimoto, K | 1 |
| Khong, TK; Sylvester, RD | 1 |
| Fletcher, RA; Heerspink, HJL; Neuen, BL | 1 |
| Füeßl, L; Schönermarck, U; Wehrmann, F | 1 |
| Agarwal, R; Farag, YMK; Singh, AK | 1 |
| Baigent, C; Haynes, R; Herrington, WG | 1 |
| Chertow, GM; Heerspink, HJL; Schechter, M | 1 |
| Patoulias, D | 1 |
| Canivell, S; Franch-Nadal, J; Gratacòs, M; Mata-Cases, M; Mauricio, D; Real, J; Vlacho, B | 1 |
| Fukuda, S; Hosokawa, K; Ida, A; Isomoto, H; Iyama, T; Kanda, T; Koda, M; Mae, Y; Matono, T; Sugihara, T; Takata, T; Taniguchi, S; Yamamoto, M | 1 |
| Cherney, DZI; Hantel, S; Inzucchi, SE; Koitka-Weber, A; Mayer, GJ; von Eynatten, M; Wanner, C; Weir, MR; Zinman, B | 2 |
| Beltrán-Romero, LM; León-Jiménez, D; Miramontes-González, JP; Moreno-Obregón, F | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Langkilde, AM; Lindberg, M; McMurray, J; Rossing, P; Stefansson, BV; Toto, R; Wheeler, DC | 1 |
| Inoue, T; Kusakabe, T; Odori, S; Satoh-Asahara, N; Shimatsu, A; Tanaka, M; Yamakage, H | 1 |
| Amemiya, H; Asakura, T; Iemitsu, K; Ishikawa, M; Ito, S; Kanamori, A; Kaneshiro, M; Kawata, T; Kubota, A; Machimura, H; Matsuba, I; Matsuzawa, Y; Minagawa, F; Minami, N; Miyakawa, M; Mokubo, A; Shinoda, K; Takai, M; Takeda, H; Takihata, M; Takuma, T; Tanaka, K; Tanaka, Y; Terauchi, Y | 1 |
| Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Hveem, K; Jonasson, C; Melbye, M; Pasternak, B; Svanström, H; Svensson, AM; Ueda, P; Wintzell, V | 1 |
| Bakris, GL; Sternlicht, HK | 1 |
| Batiushin, M; Bilchenko, O; Cherney, DZI; Chertow, GM; Correa-Rotter, R; Douthat, W; Dwyer, JP; Escudero, E; Furuland, H; Górriz, JL; Greene, T; Haller, H; Heerspink, HJL; Hou, FF; Isidto, R; Kang, SW; Kashihara, N; Khullar, D; Langkilde, AM; Lindberg, M; Mark, PB; McMurray, JJV; Nowicki, M; Pecoits-Filho, R; Persson, F; Rossing, P; Sjöström, CD; Stefansson, BV; Toto, RD; Umanath, K; Van Bui, P; Wheeler, DC; Wittmann, I | 1 |
| Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Brunner-La Rocca, HP; Butler, J; Carson, P; Choi, DJ; Chopra, V; Chuquiure, E; Cotton, D; Filippatos, G; Giannetti, N; Gonzalez Juanatey, JR; Jamal, W; Janssens, S; Januzzi, J; Kaul, S; Kimura, K; Merkely, B; Nicholls, SJ; Packer, M; Perrone, S; Pina, I; Pocock, SJ; Ponikowski, P; Sattar, N; Schnee, J; Senni, M; Seronde, MF; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Wanner, C; Zannad, F; Zeller, C; Zhang, J | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Langkilde, AM; Lindberg, M; Mann, JFE; McMurray, JJV; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| George, JT; Hantel, S; Koitka-Weber, A; Levin, A; Perkovic, V; von Eynatten, M; Wanner, C; Wheeler, DC | 1 |
| Argyropoulos, C; Ziaolhagh, A | 1 |
| Anand, IS; Bengtsson, O; Böhm, M; Chopra, V; de Boer, RA; Desai, AS; Docherty, KF; Ge, J; Heerspink, HJL; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Merkley, B; O'Meara, E; Ponikowski, P; Sabatine, MS; Shou, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S; Verma, S; Vinh, PN | 1 |
| Doumas, M; Imprialos, K; Papadopoulos, C; Patoulias, D; Stavropoulos, K | 1 |
| Nangaku, M | 1 |
| Aaron, M; Collins, SP; Cox, ZL; Davidson, BT; Fowler, M; Hernandez, GA; Iii, ATM; Jenkins, CA; Jr, FEH; Kampe, C; Lindenfeld, J; Lindsell, CJ; Miller, KF; Stubblefield, WB | 1 |
| Haynes, R; Judge, PK | 1 |
| Anker, SD; Bocchi, EA; Böhm, M; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Januzzi, JL; Khan, MS; Lam, CSP; Marx, N; Ofstad, AP; Packer, M; Perrone, SV; Pocock, SJ; Ponikowski, P; Schnaidt, S; Verma, S; Zannad, F | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Held, C; Hou, FF; Jongs, N; Langkilde, AM; Mann, JFE; McMurray, JJV; Postmus, D; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Liuzzo, G; Patrono, C | 1 |
| Khunti, K | 1 |
| Cauchon, M; Lanthier, L; Masse, M; Plourde, MÉ | 1 |
| Ambery, P; Berwanger, O; Buenconsejo, J; Chopra, V; Esterline, R; Gasparyan, SB; Javaheri, A; Koch, GG; Kosiborod, M; Langkilde, AM; Martinez, F; Mukhtar, O; Oscarsson, J; Sjöström, CD; Verma, S | 1 |
| Papaetis, GS | 1 |
| Chertow, GM; Correa-Rotter, R; Greene, T; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Rossing, P; Sjöström, CD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Tuttle, KR | 2 |
| Al-Shama, R; Eringa, EC; Hamer, HM; Juni, RP; Koolwijk, P; Kuster, DWD; van der Velden, J; van Hinsbergh, VWM; Vervloet, MG | 1 |
| Vogt, L | 1 |
| Isobe, S; Yasuda, H | 1 |
| Heerspink, HJL; Langkilde, AM; Wheeler, DC | 1 |
| LeMaistre, FI; Molony, DA | 1 |
| Larmour, K; Levin, A | 1 |
| Pirklbauer, M | 1 |
| Floege, J; Marx, N | 1 |
| Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Hou, FF; Jongs, N; Kosiborod, M; Kurlyandskaya, R; Langkilde, AM; McMurray, JJV; Rossing, P; Sjöström, CD; Stefansson, BV; Toto, RD; Wheeler, DC | 1 |
| Bhatt, DL; Cahn, A; Dwyer, JP; Gause-Nilsson, I; Goodrich, EL; Heerspink, HHJL; Im, K; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
| Goh, GH; Leo, CCH; Leong, LCY; Sia, CSM; Wong, ETY | 1 |
| Barratt, J; Floege, J | 1 |
| Burtey, S; Dou, L | 1 |
| Kohn, OF | 1 |
| Santos-Gallego, CG; Van Spall, HGC | 1 |
| Jafar, TH | 1 |
| Dabal, TD; Jackson, CD; Patrick, SA | 1 |
| Bajaj, HS; Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Persson, F; Rossing, P; Stefansson, BV; Toto, RD; Vart, P; Wheeler, DC | 1 |
| Chertow, GM; Correa-Rotter, R; Heerspink, HJL; Hou, FF; Jongs, N; Langkilde, AM; McMurray, JJV; Postmus, D; Rossing, P; Sjöström, CD; Solomon, SD; Stefánsson, BV; Toto, RD; Wheeler, DC | 1 |
| Anders, HJ; Ma, Q; Steiger, S | 1 |
| Broedl, UC; Cherney, DZI; Cooper, ME; Johansen, OE; Lund, SS; Pfarr, E; Tikkanen, I; Woerle, HJ | 1 |
| Bakris, G; Plutzky, J | 1 |
| Cain, V; Dekkers, CCJ; Heerspink, HJL; Sjöström, CD; Stefansson, BV; Wheeler, DC | 1 |
| Chang, WX; Kumagai, T; Shibata, S; Tamura, Y; Uchida, S | 1 |
| Moist, L | 1 |
| de Albuquerque Rocha, N; McCullough, PA; McGuire, DK; Neeland, IJ; Toto, RD | 1 |
| Hitomi, H; Kitabayashi, C; Kobara, H; Kobori, H; Konishi, Y; Li, L; Masaki, T; Morikawa, T; Nakano, D; Nishiyama, A; Zhang, Y | 1 |
| Atkin, SL; Butler, AE; Katsiki, N; Sahebkar, A; Yaribeygi, H | 1 |
| Benigni, A; Buelli, S; Cassis, P; Cerullo, D; Corna, D; Locatelli, M; Morigi, M; Remuzzi, G; Villa, S; Zanchi, C; Zoja, C | 1 |
| Iida, S; Ikeda, S; Kasahara-Ito, N; Portron, A; Saito, T; Schwab, D; Takano, Y | 1 |
| Marx, N; Wanner, C | 1 |
| Duan, JA; Jiang, S; Tao, JH; Xu, BH; Zhang, W; Zhao, M | 1 |
| Koh, KK | 1 |
| von Eynatten, M; Wanner, C; Zinman, B | 1 |
| Gürke, L; Tampaki, EC; Tampakis, A | 1 |
| Hantel, S; Kadowaki, T; Koitka-Weber, A; Nangaku, M; Okamura, T; von Eynatten, M; Wanner, C | 1 |
| Akimoto, T; Imai, T; Maeshima, A; Masuda, T; Miki, A; Miyazawa, Y; Murakami, T; Muto, S; Myoga, A; Nagata, D; Nakagawa, S; Ohara, K; Okada, M; Saito, O; Sekiguchi, C; Sugase, T; Yoshizawa, H | 1 |
| Scholtes, RA; van Baar, MJB; van Raalte, DH | 1 |
| Cobble, ME; Kluger, AY; Lee, AY; Lepor, NE; Lerma, EV; McCullough, PA; Rangaswami, J; Tecson, KM | 1 |
| Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Meininger, G; Usiskin, K; Wajs, E; Xi, L; Yale, JF; Yue, D | 1 |
| Gilbert, RE | 3 |
| Jones, B | 1 |
| Musetti, C; Quaglia, M; Stratta, P | 2 |
| Remuzzi, G; Ruggenenti, P | 1 |
| Barnett, AH; Broedl, UC; Jones, R; Manassie, J; Mithal, A; Rattunde, H; Woerle, HJ | 1 |
| Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Jiang, J; Law, G; Meininger, G; Nieto, J; Usiskin, K; Wajs, E; Yale, JF; Yue, D | 1 |
| Bakris, G; Davies, M; de Zeeuw, D; Kline, I; Mayer, C; Meininger, G; Perkovic, V; Usiskin, K; Vijapurkar, U; Woo, V; Yamout, H | 1 |
| Broedl, UC; Burns, KD; Cherney, DZ; Johansen, OE; Perkins, BA; Soleymanlou, N; von Eynatten, M; Woerle, HJ; Xiao, F; Zimpelmann, J | 1 |
| Scheen, AJ | 1 |
| Du, L; Duan, JA; Guo, J; Jiang, S; Liu, P; Qian, D; Shang, EX; Su, SL; Tao, J; Zhao, M | 2 |
| Gilbert, RE; Kepecs, DM; Thai, K; Zhang, Y | 1 |
| Weir, MR | 1 |
| Cain, VA; Fioretto, P; Johnsson, E; Sjöström, CD; Stefansson, BV | 1 |
| Breyer, MD; Susztak, K | 1 |
| Kazazis, C; Trigkidis, K; Vallianou, NG | 1 |
| Ferrannini, E; Kadokura, T; Smulders, RA; Veltkamp, SA | 1 |
18 review(s) available for glucose, (beta-d)-isomer and Chronic Kidney Diseases
| Article | Year |
|---|---|
Advances of the experimental models of idiopathic membranous nephropathy (Review).
Topics: Animals; Complement Membrane Attack Complex; Disease Models, Animal; Glomerulonephritis, Membranous; Humans; Kidney; Kidney Glomerulus; Models, Theoretical; Podocytes; Receptors, Phospholipase A2; Renal Insufficiency, Chronic; Thrombospondins; Zymosan | 2020 |
In brief: Dapagliflozin (Farxiga) for chronic kidney disease.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin for the treatment of chronic kidney disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Dapagliflozin in people with chronic kidney disease.
Topics: Benzhydryl Compounds; Glucosides; Humans; Renal Insufficiency, Chronic | 2023 |
Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria.
Topics: Albuminuria; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Diseases; Chronic Disease; Disease Models, Animal; Disease Progression; Drug Combinations; Glucosides; Heart Failure; Humans; Mice; Natriuretic Peptides; Neprilysin; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Valsartan | 2021 |
SGLT2 inhibitors in people with and without T2DM.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Glucosides; Heart Failure; Hospitalization; Humans; Mortality; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Empagliflozin and the Diabetic Kidney: Pathophysiological Concepts and Future Challenges.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic; Treatment Outcome | 2021 |
Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Topics: Allopurinol; Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Progression; Enzyme Inhibitors; Febuxostat; Glucosides; Gout Suppressants; Humans; Hyperuricemia; Monosaccharide Transport Proteins; Nitriles; Oxidative Stress; Pyridines; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid; Xanthine Oxidase | 2018 |
Effects of sodium glucose co-transporter 2 inhibitors on the kidney.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways.
Topics: Benzhydryl Compounds; Blood Pressure; Canagliflozin; Disease Progression; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid | 2018 |
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Renal Insufficiency, Chronic; Risk; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Glucosides; Humans; Kidney; Protective Factors; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2019 |
Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Glomerulus; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid | 2014 |
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.
Topics: Albuminuria; Benzhydryl Compounds; Canagliflozin; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Developing Treatments for Chronic Kidney Disease in the 21st Century.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atrasentan; Benzhydryl Compounds; Canagliflozin; Diabetic Nephropathies; Drug Discovery; Endothelin Receptor Antagonists; Glucosides; Glycosaminoglycans; Humans; Hypoglycemic Agents; Mineralocorticoid Receptor Antagonists; Oleanolic Acid; Oxidative Stress; Pyridoxamine; Pyrrolidines; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Sodium glucose co-transporter 2 inhibitors and their nephroprotective potential
.
Topics: Angiotensins; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Kidney; Kidney Glomerulus; Protective Agents; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Vasoconstriction | 2017 |
28 trial(s) available for glucose, (beta-d)-isomer and Chronic Kidney Diseases
| Article | Year |
|---|---|
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Incidence; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucosides; Humans; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hyperkalemia; Hypoglycemic Agents; Renal Insufficiency, Chronic | 2022 |
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD Trial.
Topics: Benzhydryl Compounds; Echocardiography; Glucosides; Humans; Renal Insufficiency, Chronic | 2023 |
Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; White | 2023 |
Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED).
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic | 2023 |
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2020 |
Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Uric Acid; Young Adult | 2020 |
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Prognosis; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Proportional Hazards Models; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Dapagliflozin in Patients with Chronic Kidney Disease.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Male; Middle Aged; Regression Analysis; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
Topics: Adams-Stokes Syndrome; Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Genital Diseases, Female; Genital Diseases, Male; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Infections; Male; Middle Aged; Mortality; Myocardial Infarction; Placebos; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
Topics: Acute Disease; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Disease Progression; Glucosides; Heart Failure; Hospital Mortality; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Hypotension; Hypovolemia; Insulin; Natriuresis; Natriuretic Peptide, Brain; Patient Readmission; Peptide Fragments; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2021 |
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Renal Insufficiency, Chronic | 2021 |
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Topics: Atherosclerosis; Benzhydryl Compounds; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cause of Death; Comorbidity; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Glucosides; Heart Failure; Humans; Hypertension; Kidney Diseases; Mortality; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Respiratory Insufficiency; SARS-CoV-2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Renal Insufficiency, Chronic; Treatment Outcome | 2021 |
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic | 2021 |
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Renal Elimination; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
Topics: Albuminuria; Asian People; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Follow-Up Studies; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Prognosis; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Analysis from the EMPA-REG OUTCOME
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Benzhydryl Compounds; Calcium Channel Blockers; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Diuretics; Female; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Male; Middle Aged; Protective Agents; Regional Blood Flow; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
Topics: Aged; Biomarkers; Blood Glucose; Body Weight; Canagliflozin; Comorbidity; Diabetes Mellitus, Type 2; Disease Progression; Diuresis; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Urinary Tract Infections | 2013 |
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2014 |
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Renal Insufficiency, Chronic; Treatment Outcome | 2016 |
80 other study(ies) available for glucose, (beta-d)-isomer and Chronic Kidney Diseases
| Article | Year |
|---|---|
Eligibility for SGLT2 Inhibitors in Heart Failure Without the Race Coefficient for Kidney Function Estimation.
Topics: Aged; Benzhydryl Compounds; Black or African American; Eligibility Determination; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Cost-Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Glucosides; Humans; Quality-Adjusted Life Years; Renal Insufficiency, Chronic; Standard of Care; Thailand | 2022 |
SGLT2 inhibitors may prevent diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease.
Topics: Adult; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Quality-Adjusted Life Years; Renal Insufficiency, Chronic; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Is Dapagliflozin future for CKD?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic | 2022 |
Could SGLT2 inhibitors be the next 'game changer' in focal segmental glomerulosclerosis?
Topics: Benzhydryl Compounds; Glomerulosclerosis, Focal Segmental; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Kidney Transplantation; Male; Metabolic Syndrome; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Dapagliflozin and the initial glomerular filtration rate decline in advanced-stage non-diabetic chronic kidney disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2022 |
Topics: Benzhydryl Compounds; Glucosides; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic | 2022 |
Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan.
Topics: Cost-Benefit Analysis; Glucosides; Humans; Japan; Renal Insufficiency, Chronic | 2022 |
Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
Topics: Adult; Benzhydryl Compounds; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Renal Insufficiency, Chronic; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic | 2022 |
Summary for Patients: Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Kidney; Renal Insufficiency, Chronic | 2023 |
The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD.
Topics: Aged; Benzhydryl Compounds; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Renal Insufficiency, Chronic; Uric Acid | 2023 |
[In patients with moderate chronic kidney disease, including non-diabetic patients, does empagliflozin provide renal and cardiovascular benefit compared to placebo, and is it safe?]
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Insufficiency, Chronic | 2023 |
Topics: Benzhydryl Compounds; Glucosides; Humans; Patients; Renal Insufficiency, Chronic | 2023 |
Empagliflozin in Patients with Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Glucosides; Humans; Patients; Renal Insufficiency, Chronic | 2023 |
Empagliflozin in Patients with Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Glucosides; Humans; Patients; Renal Insufficiency, Chronic | 2023 |
Empagliflozin in Patients with Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Glucosides; Humans; Patients; Renal Insufficiency, Chronic | 2023 |
Empagliflozin in Patients with Chronic Kidney Disease. Reply.
Topics: Benzhydryl Compounds; Glucosides; Humans; Patients; Renal Insufficiency, Chronic | 2023 |
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Kidney; Renal Insufficiency, Chronic | 2023 |
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Kidney; Renal Insufficiency, Chronic | 2023 |
In brief: Empagliflozin (Jardiance) for chronic kidney disease.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic | 2023 |
How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Eligibility Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Reproducibility of Results; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Spain | 2019 |
Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules.
Topics: Animals; Apoptosis; Disease Models, Animal; Down-Regulation; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Glucosides; Heat-Shock Proteins; Male; Mice; Non-alcoholic Fatty Liver Disease; Renal Insufficiency, Chronic; Thiophenes; Transcription Factor CHOP; Triglycerides | 2019 |
The authors reply.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Hemodynamics; Humans; Renal Insufficiency, Chronic | 2020 |
Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Glucosides; Hemodynamics; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
Topics: Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2020 |
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Comorbidity; Denmark; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Hospitalization; Humans; Kidney Diseases; Male; Middle Aged; Norway; Proportional Hazards Models; Renal Insufficiency, Chronic; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors; Sweden | 2020 |
Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?
Topics: Albuminuria; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus; Double-Blind Method; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
SGLT2 Inhibitors across the Spectrum of Severity of CKD.
Topics: Benzhydryl Compounds; Double-Blind Method; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Humans; Kidney; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2021 |
More reasons to use SGLT2 inhibitors: EMPEROR-reduced and DAPA-CKD.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
Topics: Aged; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Management of chronic kidney disease and its cardiovascular complications: has the dawn of a new era arrived? Comment on 'Dapagliflozin in Patients with Chronic Kidney Disease'.
Topics: Benzhydryl Compounds; Cardiovascular System; Glucosides; Humans; Renal Insufficiency, Chronic | 2020 |
[In patients with moderate chronic kidney disease with albuminuria, including non-diabetic patients, does dapagliflozin provide renal and cardiovascular benefit compared to placebo?]
Topics: Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2021 |
SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 | 2021 |
Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction.
Topics: Animals; Benzhydryl Compounds; Endothelial Cells; Endothelium; Endothelium, Vascular; Glucosides; Humans; Myocytes, Cardiac; Nitric Oxide; Rats; Renal Insufficiency, Chronic | 2021 |
Dapagliflozin in Patients with Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Glucosides; Humans; Renal Insufficiency, Chronic | 2021 |
Dapagliflozin in Patients with Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Glucosides; Humans; Renal Insufficiency, Chronic | 2021 |
Dapagliflozin in Patients with Chronic Kidney Disease. Reply.
Topics: Benzhydryl Compounds; Glucosides; Humans; Renal Insufficiency, Chronic | 2021 |
In CKD, dapagliflozin reduced a composite of eGFR decline, end-stage kidney disease, or CV or renal mortality.
Topics: Benzhydryl Compounds; ErbB Receptors; Glomerular Filtration Rate; Glucosides; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic | 2021 |
Slowing Progression in CKD: DAPA CKD and Beyond.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Glucosides; Humans; Mineralocorticoid Receptor Antagonists; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Anti-inflammatory potential of Empagliflozin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzhydryl Compounds; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial.
Topics: Benzhydryl Compounds; Glucosides; Humans; Renal Insufficiency, Chronic | 2021 |
Empagliflozin-induced severe osmotic nephrosis and acute renal injury in advanced chronic kidney disease.
Topics: Acute Kidney Injury; Benzhydryl Compounds; Glucosides; Humans; Kidney; Nephrosis; Renal Insufficiency, Chronic | 2021 |
SGLT-2 inhibition in IgA nephropathy: the new standard of care?
Topics: Benzhydryl Compounds; Glomerulonephritis, IGA; Glucosides; Humans; Immunosuppressive Agents; Kidney; Renal Insufficiency, Chronic; Standard of Care | 2021 |
Reversing endothelial dysfunction with empagliflozin to improve cardiomyocyte function in cardiorenal syndrome.
Topics: Benzhydryl Compounds; Cardio-Renal Syndrome; Endothelial Cells; Endothelium; Glucosides; Humans; Myocytes, Cardiac; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
In CKD, the effect of dapagliflozin on kidney outcomes did not vary by T2DM status or CKD cause.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2021 |
In HFrEF, adding empagliflozin to medical therapy reduced a composite outcome, regardless of CKD status.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Renal Insufficiency, Chronic; Stroke Volume | 2021 |
FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?
Topics: Benzhydryl Compounds; Drug Approval; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; United States; United States Food and Drug Administration | 2021 |
Dapagliflozin Improves the Clinical Outcomes of Patients with Chronic Kidney Disease and Albuminuria.
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2021 |
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease.
Topics: Animals; Benzhydryl Compounds; Blood Urea Nitrogen; Disease Models, Animal; Glomerular Filtration Rate; Glucosides; Hepatitis A Virus Cellular Receptor 1; Kidney; Mice; Mice, Inbred C57BL; Oxalic Acid; Protective Agents; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Tissue Inhibitor of Metalloproteinase-2 | 2017 |
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Pressure; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Down-Regulation; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Kidney; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2018 |
Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Renal Insufficiency, Chronic; Sodium | 2018 |
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Blood Pressure; Body Weight; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Hospitalization; Humans; Renal Insufficiency, Chronic | 2018 |
Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats.
Topics: Administration, Oral; Angiotensin II; Angiotensinogen; Animals; Disease Models, Animal; Glucosides; Glycosuria; Indoles; Kidney; Male; Nephrectomy; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Renin; Renin-Angiotensin System; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.
Topics: Animals; Benzhydryl Compounds; Cell Line; Disease Models, Animal; Glucosides; Humans; Injections, Intraperitoneal; Male; Mice; Podocytes; Proteinuria; Renal Insufficiency, Chronic; RNA, Small Interfering; Serum Albumin, Bovine; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
UPLC-Q-TOF/MS-based metabolic profiling comparison of four major bioactive components in normal and CKD rat plasma, urine and feces following oral administration of Cornus officinalis Sieb and Rehmannia glutinosa Libosch herb couple extract.
Topics: Administration, Oral; Animals; Case-Control Studies; Chromatography, High Pressure Liquid; Cornus; Feces; Glucosides; Glycosides; Iridoid Glucosides; Iridoids; Male; Phenols; Plant Extracts; Rats; Rehmannia; Renal Insufficiency, Chronic; Tandem Mass Spectrometry | 2018 |
Letter by Koh Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic | 2018 |
Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic | 2018 |
Letter by Tampakis et al Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Renal Insufficiency, Chronic | 2018 |
Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzhydryl Compounds; Body Composition; Female; Fluid Shifts; Furosemide; Glucosides; Humans; Male; Prospective Studies; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance; Water-Electrolyte Imbalance | 2019 |
SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease.
Topics: Adamantane; Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Glucosides; Humans; Incretins; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 | 2019 |
SGLT2 inhibitors' interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Chronic kidney disease: empagliflozin-one step closer to glycaemic control in patients with type II diabetes and CKD?
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic | 2014 |
The Author's Reply:.
Topics: Animals; Benzhydryl Compounds; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Thiophenes | 2014 |
A nephrologist's point of view on sodium-glucose linked transporter-2 inhibitors: not all that glitters is gold.
Topics: Animals; Benzhydryl Compounds; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Thiophenes | 2014 |
Dreaming of normoglycaemia with fewer diet restrictions.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic | 2014 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Severity of Illness Index; Thiophenes; Treatment Outcome | 2014 |
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes.
Topics: Animals; Benzhydryl Compounds; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Thiophenes | 2014 |
The author replies.
Topics: Animals; Benzhydryl Compounds; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Thiophenes | 2014 |
The authors reply.
Topics: Animals; Benzhydryl Compounds; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Thiophenes | 2014 |
Comparative pharmacokinetics of catalpol and acteoside in normal and chronic kidney disease rats after oral administration of Rehmannia glutinosa extract.
Topics: Administration, Oral; Animals; Chromatography, High Pressure Liquid; Drug Stability; Drugs, Chinese Herbal; Glucosides; Iridoid Glucosides; Linear Models; Male; Mass Spectrometry; Phenols; Rats; Rats, Sprague-Dawley; Rehmannia; Renal Insufficiency, Chronic; Reproducibility of Results; Sensitivity and Specificity | 2015 |
Simultaneous determination of loganin, morroniside, catalpol and acteoside in normal and chronic kidney disease rat plasma by UPLC-MS for investigating the pharmacokinetics of Rehmannia glutinosa and Cornus officinalis Sieb drug pair extract.
Topics: Administration, Oral; Animals; Chromatography, High Pressure Liquid; Cornus; Drugs, Chinese Herbal; Glucosides; Glycosides; Iridoid Glucosides; Iridoids; Limit of Detection; Male; Mass Spectrometry; Phenols; Rats; Rats, Sprague-Dawley; Rehmannia; Renal Insufficiency, Chronic | 2016 |
Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
Topics: Animals; Benzhydryl Compounds; Disease Models, Animal; Disease Progression; Fibrosis; Gene Expression; Glomerular Filtration Rate; Glucosides; Glycosuria; Humans; Hypertension, Renal; Hypoglycemic Agents; Kidney; Male; Nephrectomy; Proteinuria; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta1; Treatment Failure | 2016 |
Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glomerular Filtration Rate; Glucose; Glucosides; Glycosuria; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |